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Edited by Lukas HuberAbstract JNK pathway is an important pro-apoptotic kinase
cascade mediating cell death in response to a variety of extracel-
lular stimuli including excitotoxicity, which results in selective
and delayed neuronal death in the hippocampal CA1. On the
contrary, activation of the protein kinase Akt, which is con-
trolled by the opposing actions of PI3K and PTEN, contributes
to enhanced resistance to apoptosis through multiple mecha-
nisms. We here demonstrate that the temporal pattern of Akt
activation reversely correlates with JNK1/2 activation following
various time points of ischemic reperfusion. However, the activa-
tion of JNK1/2 could be decreased by the elevation of Akt acti-
vation via increasing the tyrosine phosphorylation of PTEN by
bpv(pic), a potent PTPases inhibitor for PTEN, or by intracer-
ebroventricular infusion of PTEN antisense oligodeoxynucleo-
tides (AS-ODNs). In contrast, JNK1/2 activation was
signiﬁcantly increased by preventing PTEN degradation after
pretreatment with proteasome inhibitor. The neuroprotective ef-
fects of bpv(pic) and PTEN AS-ODNs were signiﬁcant in the
CA1 subﬁeld after transient global ischemia. In conclusion, the
present results clearly show that PTEN plays a key regulatory
role in the cross-talk between cell survival PI3K/Akt pathway
and pro-death JNK pathway, and raise a new possibility that
agents targeting phosphatase PTEN may oﬀer a great promise
to expand the therapeutic options in protecting neurons form
ischemic brain damage.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The c-Jun N-terminal kinase/stress-activated protein kinase
(JNK/SAPK) is one of the mitogen-activated protein kinase
(MAPK) modules activated by variety of extracellular stimuli
and environmental stress including proinﬂammatory cyto-
kines, oxidative stress, heat shock, and ischemia [1,2]. The sig-
nals in stress-activated JNK pathway are transmitted through
three core modules: MAP3Ks such as members of the mixed
lineage kinases (MLKs) or apoptosis signal-regulated kinase
1 (ASK1), a MAP2K such as MAPK kinase 4 (MKK4) or
MKK7, and MAPK such as JNK family members [3,4]. The
activated MAP3K phosphorylates and activates MKK7 or
MKK4, which in turn phosphorylates and activates JNK.
JNK may inﬂuence the cell death process both by transcrip-
tional inducing death-promoting genes and by modulating
the mitochondria-dependent pathway via non-transcriptional
mechanisms [5,6]. Therefore, one mechanism of cell survival
may be to block JNK signaling pathway.
The cellular decision to undergo either cell death or cell sur-
vival is determined by the integration of multiple survival and
death signals. The activation of phosphatidylinositol 3-kinase
(PI3K) correlates with increased cell survival, and this eﬀect
is largely mediated through the activation of a serine/threonine
kinase Akt (also known as PKB). In previous studies, phos-
phorylation of Akt (Thr-308 and Ser-473) by phosphoinosi-
tide-dependent protein kinase-1 and serine/threonine kinases,
including an integrin-linked kinase, was responsible for Akt
activation [7,8]. The PI3K/Akt pathway promotes cellular sur-
vival, in part, by phosphorylating and inhibiting death-induc-
ing proteins, including glycogen synthase kinase 3 (GSK-3),
Bcl-2/BclxL-associated death protein (BAD), caspase 9, Fork-
head transcription factors [9–12]. Recently, active Akt has
been reported to phosphorylate and inactivate components
of the JNK pathway, including ASK1, MLK3 and MKK4
[13–16], thereby inducing antiapoptotic eﬀects.
PTEN (phosphatase and tensin homologue deleted on chro-
mosome 10) is a 58–60 kDa lipid phosphatase and tumor
suppressor protein that is frequently mutated in tumor cells
[17]. It plays a key role in cell migration, survival and apopto-
sis by negatively regulating phosphoproteins in the PI3K/Akt
pathway. PTEN is a major negative regulator of the PI3K/
Akt signaling pathway by catalyzing degradation of the phos-
phatidylinositol (PI)-3,4,5-triphosphate (PIP3) to PI-4,5-
diphosphate [18]. Structurally, PTEN protein is composed of
an N-terminal dual speciﬁcity phosphatase-like enzyme do-
main and a C-terminal regulation domain. The latter has beenblished by Elsevier B.V. All rights reserved.
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half-life of the molecule [19]. It has been reported that the pro-
tein kinase casein kinase 2 (CK2) could phosphorylate PTEN
at its C terminal and aﬀect PTEN protein stability and func-
tion. The phosphorylation of three speciﬁc residues (S380,
T382, and T383) on noncatalytic regulatory domain is required
to maintain PTEN in a stable yet relatively inactive state, and
may play an important role in control of its biological activity
[20]. In addition, PTEN contains 23 tyrosine residues; previous
data demonstrated that the phosphorylation of PTEN tyrosine
residues could negatively regulate the PTEN function [21,22].
Recently, there has been increased interest in the role of
PTEN in cellular function, particularly in neurons [23,24].
Although studies suggest that downregulation of PTEN may
play a neuroprotective role in neurodegenerative disorders that
involve excitotoxicity and apoptosis [25,26], the underlying
mechanisms still need to be established. The present study
was undertake to examine the regulation of the balance be-
tween Akt and JNK pathways through modulating the phos-
phorylation and expression of PTEN in rat hippocampal
CA1 region, and to determine the potential mechanism under-
lying PTEN downregulation against ischemic neuronal injury.2. Materials and methods
2.1. Materials
Antibodies to phospho-Akt (Ser473, #4058), Akt (#9272), PTEN
(#9559), phospho-PTEN (Ser380, #9551) and phospho-Akt (Ser473,
#3787, IHC Speciﬁc) were from Cell Signaling Technology, Inc. (Bev-
erly, MA, USA). Anti-active (diphosphorylated) JNK1/2 antibody,
BCIP (5-bromo-4-chloro-3-indolyl-phosphate) and NBT (nitroblue
tetrazolium) were from Promega (Madison, WI, USA). Anti-JNK1/2
antibody, calpain Inhibitor I (A6185), alkaline phosphatase conju-
gated goat anti-rabbit IgG and goat anti-mouse IgG were all from Sig-
ma (St. Louis, MO, USA). Bpv(pic) (ALX-270-205) was obtained from
Alexis (Dianova, Hamburg, Germany). LY294002 was obtained from
Upstate Biotechnology Inc. (Lake Placid, NY, USA). All other chem-
icals were from Sigma unless indicated otherwise.
2.2. Animal model of ischemia
Adult male S.D. rats (Shanghai Experimental Animal Center, Chi-
nese Academy of Science) weighing 250–300 g were used. Cerebral
ischemia was induced by four-vessel occlusion (4-VO) as described be-
fore [27,28]. Brieﬂy, under anaesthesia with chloral hydrate (350 mg/
kg, i.p.), vertebral arteries were electrocauterized and common carotid
arteries were exposed. Rats were allowed to recover for 24 h and fasted
overnight. Ischemia was induced by occluding the common arteries
with aneurysm clips. Rats which lost their righting reﬂex within 30 s
and whose pupils were dilated and unresponsive to light during ische-
mia were selected for the experiments. Rats with seizures were dis-
carded. An EEG was monitored to ensure isoelectricity within 30 s
after carotid artery occlusion. Carotid artery blood ﬂow was restored
by releasing the clips. Rectal temperature was controlled at 36.5–
37.5 C before and after ischemia-reperfusion and after treatment with
drugs via a temperature-regulated heating pad. Sham control animals
received the same surgical procedures except that carotid arteries were
not occluded.
2.3. Drug administration
When necessary, animals were given bisperoxo(pyridine-2-car-
boxyl)oxovanadate (bpv(pic)) at a dose of 20 lg/100 g for four times
with an interval of 3 h by intraperitoneal injections, and ischemia
was induced 20 min after the last injection. Control rats received intra-
peritoneal injections of vehicle (0.9% saline). LY294002 or A6185
(25 lg in 10 ll 1% DMSO diluted in saline) was administrated to the
rats 20 min before ischemia through intracerebroventricular (i.c.v.)
injection. For i.c.v. injection, the rats were placed on ear bars of a ste-
reotaxic instrument under anesthesia. Drug infusion was performedusing a stepper-motorized microsyringe (Stoelting, Wood Dale, IL)
at a rate of 1 ll/min through a preimplanted cannula in the left cerebral
ventricle (from the bregma: anteroposterior, 0.8 mm; lateral, 1.5 mm;
depth, 3.5 mm). To investigate the possible role of PTEN in response
to ischemic injury, 10 nmol of end-phosphorothioated PTEN AS-
ODNs in 10 ll TE buﬀer (10 mM Tris–HCl (pH 8.0), 1 mM EDTA)
were administrated to the rats every 24 h for 3 days by means of
i.c.v. infusion. The same dose of missenses (MS) or vehicle (TE) was
used as controls. The sequences for PTEN AS-ODNs used in this study
were 5 0-CTGCTAGCCTCTGGATTTGA0, and missenses were 5 0-
CTTCTGGCATCCGGTTTAGA-3 0, as previously described [29].
2.4. Tissue preparation
For brain tissue preparation, rats were sacriﬁced under anesthesia at
several time points of reperfusion after 15 min of global cerebral ische-
mia. Whole brains were removed for dissections and the hippocampal
CA1 regions were microdissected from both sides of the hippocampal
ﬁssure and immediately frozen in liquid nitrogen. Tissues were homog-
enized in ice-cold homogenization medium consisting of 50 mM
HEPES (pH 7.4), 150 mM NaCl, 12 mM b-glycerophosphate, 3 mM
dithiotheitol (DTT), 2 mM sodium orthovanadate (Na3VO4), 1 mM
EGTA, 1 mM NaF, 1 mM phenylmethylsulfonyl ﬂuoride (PMSF),
1% Triton X-100, and inhibitors of protease and enzymes. The homog-
enates were centrifuged at 15000 · g for 20 min at 4 C, supernatants
were collected and stored at 80 C for use. The protein concentra-
tions were determined by the method of Lowry with bovine serum
albumin as standard.
2.5. Immunoprecipitation and Western blotting
For immunoprecipitation, the cytosolic fractions (each containing
400 lg of proteins) were diluted fourfold with HEPES buﬀer contain-
ing 50 mM HEPES (pH 7.4), 150 mM NaCl, 10% glycerol, 1% Triton
X-100, and 1 mM each of EGTA, EDTA, PMSF and Na3VO4. Sam-
ples were pre-incubated for 1 h with 20 ll protein A/G then centrifuged
to remove any protein adhered nonspeciﬁcally to the protein A/G. The
supernatant was incubated with 2–5 lg proper antibodies for 4 h at
4 C. After the addition of Protein A/G-sepharose, the mixture was
incubated at 4 C for an additional 2 h. Samples were triple washed
with HEPES buﬀer and eluted by sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis (SDS–PAGE) loading buﬀer then boiling
at 100 C for 5 min.
Western blot analysis was carried out on 10% SDS–PAGE. Brieﬂy,
proteins were electrotransferred onto nitrocellulose ﬁlter (NC, pore
size, 0.45 lm). After blocking for 3 h in PBS with 0.1% Tween 20
(PBST) and 3% BSA, the membranes were incubated over night with
primary antibody in PBST containing 3% BSA. Detection was carried
out by the use of proper alkaline phosphatase conjugated IgG
(1:20000) and developed with NBT/BCIP assay kit (Promega, Madi-
son, USA).3. Immunohistochemistry
Rats were anesthetized with chloral hydrate and underwent
transcardial perfusion with 0.9% saline followed by 4% para-
formaldehyde in 0.1 M phosphate buﬀer (PBS). Brains were re-
moved, post-ﬁxed overnight in paraformaldehyde, processed
and embedded in paraﬃn. Coronal brain sections (6 lm-thick)
were cut on a microtome (Leica RM2155, Nussloch, Ger-
many). Sections were de-paraﬃnized in xylene and rehydrated
in a gradient of ethanol and distilled water. High-temperature
antigen retrieval was performed in 1 mM citrate buﬀer. To
block endogenous peroxidase activity, sections were incubated
for 6–8 min in 3% H2O2. After being blocked with 5% (v/v)
normal goat serum in 0.01 M PBS (pH 7.4) for 1 h at 37 C,
sections were incubated with corresponding primary antibod-
ies at 4 C for 3 days. Sections were washed three times with
0.01 M PBS (pH 7.4) after each step followed. The sections
were then incubated with biotinylated secondary antibody
overnight and subsequently with stretavidin-peroxidase for
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substrate diaminobenzidine until desired stain intensity devel-
oped.
3.1. Histology
Rats were anesthetized with chloral hydrate and underwent
transcardial perfusion with 0.9% saline followed by 4% para-
formaldehyde in 0.1 M phosphate buﬀer (PBS). Brains were re-
moved, post-ﬁxed overnight in paraformaldehyde, processed
and embedded in paraﬃn. Coronal brain sections (6 lm-thick)
were cut on microtome. Sections were de-paraﬃnized in xylene
and rehydrated in a gradient of ethanol and distilled water.
The neuronal density of the hippocampal CA1 pyramidal cells
was expressed as the number of cells per 1 mm linear length of
hippocampal CA1 pyramidal layer counted under a light
microscope (·400).sham R0 R30m R3h R6h R12h R1d R3d
O
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Four or ﬁve independent animals were sampled at each time
point for Western blotting study and histology examination.
Semiquantitative analysis of the bands was performed with
the Image J analysis software (Version 1.30v; Wayne Rasband,
NIH, USA). All values are expressed as the means ± S.D. Sta-
tistical analysis of the results was carried out by one-way anal-
ysis of variance (ANOVA) followed by the least signiﬁcant
diﬀerence (LSD) test or Newman–Keuls test. Diﬀerences of
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Fig. 1. Time courses of the expression and phosphorylation of PTEN,
Akt and JNK1/2 in rat hippocampal CA1 region after transient
forebrain ischemia. (A, C, D) Immunoblotting analysis of the
phosphorylation and expression levels of PTEN, Akt and JNK1/2 at
the indicated time points after ischemic reperfusion. To detect the
tyrosine phosphorylation of PTEN, samples from hippocampal CA1
region were immunoprecipitated (IP) with anti-PTEN antibody, then
Western blotted (WB) with anti-phospho-tyrosine antibody. (B, E)
Corresponding bands were scanned and the optical density (O.D.) was
represented as folds versus sham control. Data are expressed as
means ± S.D. from four independent animals (n = 4). *P < 0.05 versus
sham control; #P < 0.05 versus groups with 30 min of reperfusion
(R30m).4. Results
4.1. Temporal patterns of the expression and phosphorylation
of PTEN, Akt and JNK1/2 in hippocampal CA1 region
following global ischemic reperfusion
We initially analyzed the protein expression of PTEN in the
postischemic hippocampal CA1 tissues by Western blot. As
shown in Fig. 1A and B, the protein level of PTEN signiﬁ-
cantly decreased at 3, 6 and 12 h of ischemic-reperfusion,
and recovered at 24 h. Similarly, the Ser-380 phosphorylation
of PTEN was decreased at the indicated time point as PTEN,
except that PTEN-Ser-380 phosphorylation signiﬁcantly de-
creased at 30 min of reperfusion. Homogenate samples of hip-
pocampal CA1 region were then immunoprecipitated with
anti-PTEN antibody and blotted with anti-phospho-tyrosine
antibody. In contrast, results showed that tyrosine phosphory-
lation of PTEN was signiﬁcantly increased at 3, 6 and 12 h of
ischemic-reperfusion compared with sham control (Fig. 1A
and B).
To study the activation of Akt protein kinase, we explored
both total Akt and Akt-Ser-473 phosphorylation in the postis-
chemic hippocampal CA1 tissues by Western blot analyses.
Total Akt was unchanged in hippocampal CA1 regions after
ischemia, but phospho-Akt was remarkably increased over
the control levels from 30 min to 12 h of reperfusion
(Fig. 1C and E). Phosphorylation of Akt returned to the con-
trol level at 24 h, with no secondary increase at 72 h of reper-
fusion. The JNK1/2 immunoreactivity at the indicated time
points after 15 min ischemia was also examined. Western blot
study, as shown in Fig. 1D and E, showed that the total pro-
tein level of JNK1/2 was not signiﬁcantly changed after reper-
fusion in hippocampal CA1 subﬁelds compared with shamoperation, while the diphosphorylation level of JNK1/2 was
signiﬁcantly increased and peaked at 30 min after ischemia
and then declined to base level 3 h after ischemia. However,
p-JNK1/2 was secondly increased and reached another peak
at 3 days after ischemia. These observations suggest that
there might be some relationship between JNK1/2 and Akt
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Fig. 2. Eﬀects of bpv(pic) on the tyrosine phosphorylation of PTEN, Ser-473 phosphorylation of Akt and the dephosphorylation level of JNK1/2 in
hippocampal CA1 region; and the eﬀects of combined treatment with LY294002 on the activation of Akt and JNK1/2. (A) Homogenate samples
from sham, vehicle and drug treatment rats at 10 min and 3 days of reperfusion were IP with anti-PTEN antibody, and then Western blotted with
anti-phospho-tyrosine antibody, or directly blotted with anti-PTEN antibody. (C, E) Immunoblotting analysis of the phosphorylation and
expression levels of Akt and JNK1/2 from the indicated homogenate samples. (B, D, F) Bands on Western blots were scanned and the intensities were
expressed as folds versus sham treatment. Values are represented as mean ±S.D. for four independent experiments (n = 4). *P < 0.05 versus saline
treatment (B, D) or sham (F) groups; #P < 0.05, signiﬁcant diﬀerence versus bpv(pic) treatment (D); aP < 0.05 versus R30m + saline groups;
bP < 0.05 versus LY294002 + bpv(pic) groups.
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Q.-G. Zhang et al. / FEBS Letters 581 (2007) 495–505 499pathways during ischemic reperfusion, and PTEN might play
some role in the linking of these two signaling systems.
4.2. Bpv(pic) pretreatment signiﬁcantly increased both the
tyrosine phosphorylation of PTEN and Akt-Ser-473
phosphorylation; dephosphorylation of JNK1/2 was
involved in Akt activation by bpv(pic) compounds
Previous report shows that several growth factors induce
PTEN phosphorylation, probably at tyrosine residues 240,
315, and 336, which is followed by decreased protein stability
and enzymatic activity [30]. To determined whether PTEN was
involved in the activation of Akt during reperfusion, we uti-
lized a well-established protein tyrosine phosphatases (PTP-
ases) inhibitor, bpv(pic), which has high preference and
potency towards PTEN [31]. Results showed that tyrosine
phosphorylation of PTEN was signiﬁcantly increased at the
early (10 min) and later (3 days) time points of reperfusion
in hippocampal CA1 regions after bpv(pic) treatment, while
PTEN protein level kept unchanged (Fig. 2A and B). Subse-Sham
a
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d
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e
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Fig. 3. Eﬀects of bpv(pic) on the delayed neuronal death by histology analys
Cresyl violet staining was performed on the sections from the hippocampi in
global ischemia (b, g), administration of saline (c, h) or bpv(pic) alone (d, i) or
inhibition clearly increased the number of survival neurons at 5 days of reperfu
and on typical experiment was presented. Scale bars: (a–e) = 400 lm; (f–j) =quent Western blot analysis showed that Akt-Ser-473 phos-
phorylation was signiﬁcantly elevated by pretreatment of
bpv(pic) both at the early and the later reperfusion periods
after 15 min ischemia (Fig. 2C and D). While Akt protein level
was not aﬀected.
To further determine whether PTEN/PI3K signaling was
associated with stress-activated JNK pathway, homogenate
samples of hippocampal CA1 were analyzed on the diphosph-
orylation level of JNK1/2 by immunoblotting using an
anti-phospho-JNK1/2 antibody. As shown in Fig. 2E and F,
phosphatase inhibition by bpv(pic) signiﬁcantly decreased
the activation of JNK both at 30 min and 3 days of reperfu-
sion. Whereas, combined treatment with the speciﬁc blockade
LY294002 of PI3K simultaneously reversed the changed acti-
vation of Akt (Fig. 2C, right panel) and JNK1/2 (Fig. 2E,
right panel) induced by bpv(pic) at 3 days of reperfusion.
These results imply that downregulation of JNK pathway
was involved in the elevation of Akt activation by bpv(pic)
treatment.f
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j
iolet staining
is in rat hippocampal CA1 region induced by global cerebral ischemia.
sham operation (a, f), and rats subjected to 5 days of reperfusion after
combined with LY294002 (e, j) before ischemia. Tyrosine phosphatase
sion in CA1 region. Data were obtained from ﬁve independent animals
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neuronal death in rat hippocampal CA1 region induced by
global cerebral ischemia
To investigate the potential neuroprotective eﬀects of
bpv(pic) against ischemic injury, histology analyses were per-
formed on the sections from sham, vehicle control and groups
treated with bpv(pic). Cresyl violet staining was used to exam-
ine the survived cells of CA1 pyramidal neurons. Normal cells
showed round and pale stained nuclei. The shrunken cells with
pyknotic nuclei after reperfusion were counted as dead cells.
As shown in Fig. 3, transient cerebral ischemia followed by 5
days of reperfusion induced severe cell death (Fig. 3b and g).
However, bpv(pic) treatment obviously limited the neuronal
degeneration (Fig. 3d and i), which was abolished by treatment
combined with LY294002 (Fig. 3e and j). The numbers of via-
ble neurons were quantitatively analyzed per 1 mm linear
length of hippocampal CA1 pyramidal layer in the diﬀerent
experimental groups. The numbers of surviving pyramidal cells
in CA1 region of single ischemia, saline treatment, bpv(pic)
treatment and combination with LY294002 animals were
13.6 ± 4.8%, 14.3 ± 5.2%, 68.6 ± 8.2% and 24.8 ± 6.5% respec-
tively of those in sham operation.sham R3d TE MS AS 
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F4.4. PTEN antisense oligodeoxynucleotides (AS-ODNs)
treatment signiﬁcantly inhibited PTEN expression,
increased and decreased the activation of Akt and
JNK1/2 in hippocampal CA1 region, respectively
To further investigate the possible relationship between
PI3K/Akt signaling and JNK pathway, we ﬁrst examined the
alteration of PTEN expression after i.c.v. injection of the
PTEN AS-ODNs. Results from Western blot analysis showed
that PTEN AS-ODNs markedly inhibited the protein expres-
sion compared with scrambled ODNs in rat hippocampal
CA1 region after reperfusion of 3 days (Fig. 4A and B).
Homogenate samples of hippocampal CA1 region were then
Western blotted with anti-phospho-Akt or anti-phospho-
JNK1/2 antibody. Interestingly, PTEN AS-ODNs treatment
signiﬁcantly increased and decreased the activation of Akt
(Fig. 4C and D) and JNK1/2 (Fig. 4E and F), respectively.
The protein expression of Akt and JNK1/2 kept unchanged.
These observations suggest that the balance between the acti-
vation of Akt and JNK pathway could be disturbed by altering
the protein level of PTEN.O
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Fig. 4. PTEN expression in rat hippocampal CA1 region after
pretreatment with PTEN AS-ODNs (AS) or the missense oligonuleo-
tides (MS); and the eﬀects on the phosphorylation and expression of
Akt and JNK1/2 following 3 days of ischemic reperfusion. (A) PTEN
protein expression in hippocampal CA1 region was detected by
Western blotting. The AS-ODNs administration signiﬁcantly reduced
PTEN expression at 3 days after ischemia. (C, E) Homogenate samples
of hippocampal CA1 region were Western blotted with anti-phospho-
Akt or anti-phospho-JNK1/2 antibody. (B, D, F) Semiquantitative
representations of corresponding protein levels. Data were expressed
as means ±S.D. derived from four independent animals (n = 4).
*P < 0.05 versus MS-treatment group; #P < 0.05 versus sham control.4.5. Knockdown of PTEN expression was neuroprotective
against delayed neuronal death induced by cerebral ischemia
in rat hippocampal CA1 subﬁeld
We next investigated the potential protective eﬀects against
ischemic injury after PTEN knockdown, Cresyl violet staining
was performed on the sections from control animals (TE only)
and animals treated with PTEN AS-ODNs, or PTEN missense
ODNs in the aforementioned groups. Normal cells showed round
and pale stained nuclei were counted as survival cells. The num-
ber of intact CA1 neurons per 1 mm linear length of hippocampal
CA1 pyramidal layer was reduced from 182.0 ± 19.0 to 20.2 ± 8.6
by global ischemia (Fig. 5f and g). Application of TE or missense
ODNs resulted in a reduction of neurons in the hippocampal
CA1 sector as 19.6 ± 6.4 (Fig. 5c and h) and 26.2 ± 6.4
(Fig. 5d and i), respectively. However, the number of intact
CA1 neurons was signiﬁcantly increased to 93.2 ± 16.2 by admin-
istration of POSH AS-ODNs (Fig. 5e and j).
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Fig. 5. Eﬀects of PTEN AS-ODNs on neuronal injury by histology analysis. Cresyl violet staining was performed on the sections from the
hippocampi in sham operation (a, f), and rats subjected to 5 days of reperfusion after 15 min of ischemia (b, g), administration of TE (c, h), PTEN
MS-ODNs (d, i) and PTEN AS-ODNs (e, j) before ischemia. Treatment with PTEN AS-ODNs clearly increased the number of the survival neurons
at 5 days of reperfusion in CA1 region. Data were obtained from ﬁve independent animals and on typical experiment was presented. Scale bars:
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decreased and increased the activation of Akt and JNK1/2 in
hippocampal CA1 region at 6 h of reperfusion, respectively
To investigate whether the degradation of PTEN following
ischemic-reperfusion is mediated by the proteasome, we in-
fused the proteasome inhibitor A6185 by i.c.v. injection before
ischemia. As shown in Fig. 6A and B, A6185 signiﬁcantly
blocked the ischemia-induced degradation of PTEN, whereas
b-actin levels were unchanged. To determine whether PTEN
degradation is required for ischemia-induced Akt activation
and the dephosphorylation of JNK1/2 at 6 h of reperfusion,
homogenate samples of CA1 region from A6185 pretreated
rats were then Western blotted with anti-phospho-Akt or
anti-phospho-JNK1/2 antibody. Rats pretreated with vehicle
only showed no eﬀects on both the activation of Akt and
JNK1/2. In contrast, pretreatment with A6185 signiﬁcantlyinhibited the activation of Akt at 6 h of ischemic reperfusion
(Fig. 6C and D). At the same time, the diphosphorylation level
of JNK1/2 in A6185 pretreated group signiﬁcantly increased
compared to vehicle control (Fig. 6E and F). Subsequent
immunocytochemical staining of coronal brain sections sup-
ported the observations from Western blotting. As shown in
Fig. 7A(a)–A(d), strong PTEN immunoreactivity was seen in
hippocampal CA1 pyramidal layer. As to the subcellular local-
ization of PTEN, note that the immunoreactivity was pre-
sented mainly in the cytosol but little in the nucleus
(Fig. 7A(e)–A(h)). The active states of Akt distributed both
in cytosol and in the nucleus, but predominately located in
cytosol (Fig. 7B(e)–B(h)). The levels of PTEN expression was
apparently increased by pretreatment with A6185 (Fig. 7A(d)
and A(h)), whereas the density of phospho-Akt immunoreac-
tivity after A6185 pretreatment was apparently decreased com-
pared to vehicle control (Fig. 7B(d) and B(h)).
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Fig. 7. Immunohistochemical analysis of the expression and subcel-
lular localization of PTEN and Ser-473 phosphorylation of Akt in rat
hippocampi after treatment of calpain inhibitor I (A6185) before
cerebral ischemia. Coronal slices (6 lm) from rats subjected to sham
operation (a, e), 15 min of cerebral ischemia followed by 6 h of
reperfusion (b, f), and rats ventricularly administrated with vehicle (c,
g) or A6185 (d, h) before ischemia. PTEN-positive cells were mainly
detected in CA1 regions of rat hippocampus. Note that PTEN
immunoreactivity was strong in cytosolic fraction in the hippocampal
pyramidal cells. The Akt-Ser-473 immunoreactivity distributed both in
cytosol and in the nucleus. Boxed areas in left column are shown at
higher magniﬁcation in right column. a, b, c, and d: magniﬁcation is
40· and the scale bar 400 lm; e, f, g and h: magniﬁcation is 400· and
the scale bar 10 lm.
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Fig. 6. Eﬀects of calpain inhibitor I (A6185) on the expression of
PTEN and the activation of Akt and JNK1/2 in hippocampal CA1
region at 6 h of reperfusion. (A, C, E) Protein samples from
hippocampal CA1 region of sham control, ischemic or drug admin-
istered rats were Western blotted with anti-PTEN, anti-phospho-Akt
and anti-phospho-JNK1/2 antibodies, respectively. (B, D, F) Corre-
sponding bands were scanned and the intensities were represented as
folds versus sham control. Data are expressed as means ±S.D. from
four independent animals. *P < 0.05 versus sham control. #P < 0.05,
signiﬁcant diﬀerence versus vehicle-treatment group.
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Considerable evidence has suggested that JNK is an impor-
tant kinase mediating neuronal cell death in response to cere-
bral ischemia [32,33]. In contrast, activation of Akt kinase
pathway can be neuroprotective after ischemia [34]. Recent
studies have suggested that Akt negatively regulates the JNK
signaling pathway and JNK-mediated apoptosis [35,36]. How-
ever, the underlying mechanism by which Akt regulates the
JNK signaling pathway remains to be elucidated. We here
demonstrated that the activation proﬁles of Akt and JNK1/2
are opposite following various time points of ischemic reperfu-
sion, especially at 3–12 h and 3 days of reperfusion. That is, the
increased Akt activation reversely correlates with the de-
creased activation of JNK1/2 at the indicated time points.
Additionally, we observed that the serine phosphorylation
and protein level of PTEN were downregulated, while tyrosine
phosphorylation of PTEN was increased following the indi-
cated time points of ischemic reperfusion. These results suggest
that the balance between Akt and JNK pathways might be reg-
ulated through modulating the phosphorylation and expres-
sion of PTEN in rat hippocampal CA1 region. To test this
hypothesis, we have used three diﬀerent pharmacological ap-
proaches targeting PTEN to study the cross-talk between
pro-survival Akt pathway and pro-death JNK pathway. More-
over, we demonstrate for the ﬁrst time that a potent tyrosine
phosphatase inhibitor bpv(pic) for PTEN and PTEN AS-
ODNs both rescued hippocampal CA1 neurons from delayed
cell death induced by global ischemia. Overall, our observa-
tions clearly show that PTEN plays a critical role in the func-
tional coupling between JNK and PI3K/Akt pathways in
ischemic brain injury.
It is well established that PTEN has phosphoinositide 3-phos-
phatase activity and plays an important role in the modulation
of the PI3K/Akt pathway. Activation of PTEN is regulated by a
balance of phosphorylation and dephosphorylation of the
protein [20,37,38]. The non-catalytic regulatory C-terminal of
PTEN contains multiple constitutive phosphorylation sites
including several CK2 sites [20]. This phosphorylation on serine
and threonine residues regulates its stability, activity, and poten-
tially its association with other proteins through its PDZ-bind-
ing motif [37–39]. Thus, phosphorylation of C-terminal domain
inactivates the phosphatase activity, and dephosphorylated
PTEN represents an active form. The active-dephosphorylated
PTEN is quickly degraded by proteasome to prevent an unti-
mely activation. PTEN also contains 23 tyrosine residues, sev-
eral of which are in consensus phosphorylation sites. Previous
data demonstrated that tyrosine phosphorylation of PTEN is
associated with decreased PTEN function and reduced PTEN
stability [21,22]. Therefore, phosphorylation on tyrosine and
serine/threonine residues both decrease the ability of PTEN to
dephosphorylate PIP3. In contrast tyrosine phosphorylation de-
creases PTEN stability and serine/threonine phosphorylation
increases PTEN stability. Indeed, as shown in the present study,
the dephosphorylation of PTEN-Ser-380 (from 30 min of reper-
fusion) preceded the degradation of PTEN (from 3 h of reperfu-
sion), whereas tyrosine phosphorylation of PTEN was
signiﬁcantly increased from 3 h to 12 h of reperfusion, which
was companied by decreased PTEN protein level. This suggests
that ischemic-reperfusion disrupted the balance of phosphoryla-
tion and dephosphorylation of PTEN, which targets the protein
for degradation.Previous ﬁndings by us and others have established that
alteration of Akt signaling pathway by non-speciﬁc PTPases
inhibitor vanadate is partly responsible for the neuroprotec-
tion in cerebral ischemia [28,40–42]. However, non-speciﬁc
inhibitors of PTPs, such as vanadate have toxic side eﬀects
at high doses [43,44]. Bpv(pic) is one of the newly discovered
bisperoxyvanadium compounds which preferentially inhibit
PTEN at nanomolar concentrations without aﬀecting cell via-
bility [31]. In this study, we chose to utilize bpv(pic) at a dose
of 144 nanomolar every injection, a very low dose which is
likely to inhibit PTEN rather than inhibit non-speciﬁc phos-
phatase such as PTP-1B or PTP-b [31]. We herein clearly show
that treatment of bpv(pic) resulted in a marked enhancement
of tyrosine phosphorylation of PTEN, which was appeared
to be independent of the changes in the total PTEN expression.
In addition, bpv(pic) markedly decreased the diphosphoryla-
tion level of JNK1/2 by enhancing Akt-Ser-473 phosphoryla-
tion. Moreover, we observed that treatment of bpv(pic)
signiﬁcantly rescued hippocampal CA1 neurons. Therefore,
the apparent potency of bpv compounds along with their rela-
tively simple and versatile structure may represent a new ave-
nue for the development of novel therapeutic agents for the
treatment of ischemic stroke.
We further demonstrated that speciﬁc downregulation of
PTEN protein level by PTEN AS-ODNs resulted in decrease
of JNK1/2 activation, which is companied by increased Akt
activation. Thus, we identiﬁed the protein phosphatase PTEN
as a crucial upstream signal to regulate JNK pathway. Impor-
tantly, our work has provided direct evidence that suppressing
the protein phosphatase PTEN, at least via downregulating
JNK1/2, protects against ischemic neuronal death. Thus, tar-
geting protein phosphatase activity of PTEN may represent a
novel pharmacological approach for stroke treatment by neg-
ative regulating JNK-mediated neuronal death.
We have shown that dephosphorylation of PTEN-Ser-380
during reperfusion precedes its degradation, which is consis-
tent with previous report that ischemia-induced dephosphoryl-
ation of PTEN is a signal for its degradation [45,46]. We found
that Calpain inhibitor I (A6185) blocks PTEN degradation in
the ischemic brain, demonstrating involvement of the protea-
some in this process. As expected, decrease of Akt activation
by A6185 was companied with the elevation of JNK1/2 activa-
tion at 6 h of reperfusion. Such reverse proﬁle of JNK1/2 and
Akt activation further suggests the potential cross-talk be-
tween the two signal systems in the postischemic brain. In-
creased calpain activity in the rat brain after transient
forebrain ischemia has been well characterized [47–49]. How-
ever, additional studies are needed to investigate the eﬀects
of proteasome inhibitors on PTEN function, especially in light
of the reported neuroprotection in the hippocampal CA1 sec-
tor following calpain inhibition [50,51].
PTEN activity is associated with down-regulated activities of
multiple downstream components of the PI3K pathway,
including most notably Akt and its downstream targets,
BAD, p70S6K, GSK3, p21, p27, MDM2, TSC1/2, and fork-
head transcription factors and altered expression of p27 [52–
55]. We and other groups have elucidated that JNK pathway
is critically involved in the ischemic brain injury after transient
forebrain ischemia [2,32]. The opposing eﬀects of JNK1/2 and
PI3K/Akt signaling in protecting neurons form ischemic dam-
age suggests that JNK cascade induced by ischemic stress
might be suppressed through activating PI3K/Akt pathway.
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between Akt and JNK have been reported. For example, acti-
vated Akt has been shown to directly inhibit JNK pathway
through phosphorylation of MLK3, MKK4 and ASK1 in
the JNK signaling cascade [13–15]. In addition, Akt1 binding
to JIP1 decreases JIP1s ability to enhance JNK activity by dis-
assembling of an active JNK signaling complex in neuronal
apoptosis [56]. Further, we have recently demonstrated that
Akt-mediated Rac1-Ser-71 phosphorylation results in decrease
in the binding of Rac1 with MLK3 and negative regulation of
the JNK signaling in rat hippocampus [28]. Taken together,
the present study ﬁrmly establishes a cross-talk between
JNK1/2 and PI3K/Akt pathways mediated by PTEN, which
also provide a functional coupling between the family of
stress-activated kinases and Akt signaling in the postischemic
brain.
In conclusion, downregulation of PTEN reﬂects an in-
creased balance to cell survival, and closely related to cell sur-
vival PI3K/Akt pathway and their downstream eﬀectors. Our
results suggest that PTEN is a central regulator of the linking
between JNK1/2 and PI3K/Akt pathways in cerebral ischemia.
Further, we demonstrate that approaches designed to inhibit
PTEN in vivo prevent ischemic injury, and may be a viable ap-
proach to the treatment of ischemic stroke. Further work will
be required to more precisely deﬁne the regulatory role of
PTEN, and the molecular mechanisms by which ischemia
modulates its activity in brain injury.
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